Found: 9
Select item for more details and to access through your institution.
Effects of Different Meal Compositions and Fasted State on the Oral Bioavailability of Etravirine.
- Published in:
- Pharmacotherapy, 2008, v. 28, n. 10, p. 1215
- By:
- Publication type:
- Article
İki Ayda Bir Enjektabl Uzun Etkili Cabotegravir + Rilpivirin (CAB + RPV) Tedavi Rejimi: ATLAS-2M Çalışması 152. Hafta Sonuçları.
- Published in:
- Mediterranean Journal of Infection, Microbes & Antimicrobials, 2022, v. 11, p. 129
- By:
- Publication type:
- Article
Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2014, v. 69, n. 3, p. 728, doi. 10.1093/jac/dkt421
- By:
- Publication type:
- Article
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
- Published in:
- Clinical Infectious Diseases, 2023, v. 77, n. 10, p. 1423, doi. 10.1093/cid/ciad370
- By:
- Publication type:
- Article
Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study.
- Published in:
- Open Forum Infectious Diseases, 2022, v. 9, n. 4, p. 1, doi. 10.1093/ofid/ofac067
- By:
- Publication type:
- Article
Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study.
- Published in:
- Open Forum Infectious Diseases, 2021, v. 8, n. 9, p. 1, doi. 10.1093/ofid/ofab439
- By:
- Publication type:
- Article
319. SWORD 1 and 2: Switch from TDF Containing Regimen to DTG+RPV Maintains Bone Mineral Density and Decreases Bone Turnover Markers Over 148 Weeks.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S169, doi. 10.1093/ofid/ofz360.392
- By:
- Publication type:
- Article
Long-Acting Cabotegravir+Rilpivirine Every 2 Months: ATLAS-2M Week 152 Results.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. 276
- By:
- Publication type:
- Article
Long-acting cabotegravir+rilpivirine every 2 months: ATLAS-2M week 152 results.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. S310
- By:
- Publication type:
- Article